Naseema Gangat - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Naseema Gangat's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Naseema Gangat

Naseema Gangat

Verified

Associate Editor, Blood Cancer Journal

Rochester

Final Covers

Migration, International Policy, eu tech, Environment , Data

Journalist Type

Seniority Positions

Industries

-

Medium Formats

Content

Total articles 73

  • Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days - Blood Cancer Journal

    By Naseema Gangat Verified, Ayalew Tefferi| Nature Verified Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.

    By Naseema Gangat Verified, Ayalew Tefferi · Nature

    Apr. 02, 2025

  • Topics of Interest in Women With Myeloproliferative Neoplasms

    By Natasha Szuber, Paola Guglielmelli, Naseema Gangat Verified| Wiley Online Library Verified 1 Introduction Sex has been identified as a key regulator of susceptibility to cancer, response to therapy, disease outcomes, and associated mortality [1]. The mechanisms underpinning sex-biased disparities include distinct genetic profiles [2], hormone patterns [3], immune responses [4], and drug metabolism [5].

    By Natasha Szuber, Paola Guglielmelli, Naseema Gangat Verified · Wiley Online Library

    Mar. 15, 2025

  • Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days - Blood Cancer Journal

    By Naseema Gangat Verified, Ayalew Tefferi| Nature Verified Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.

    By Naseema Gangat Verified, Ayalew Tefferi · Nature

    Apr. 02, 2025

As seen in

Company Info

Blood Cancer Journal

Hoboken, New Jersey, United States

'+1 201-748-6000